Abstract
Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Current Molecular Medicine
Title: Osteoprotegerin and Diabetes-Associated Pathologies
Volume: 11 Issue: 5
Author(s): A. M. Blazquez-Medela, J. M. Lopez-Novoa and C. Martinez-Salgado
Affiliation:
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Abstract: Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Blazquez-Medela A., M. Lopez-Novoa J. and Martinez-Salgado C., Osteoprotegerin and Diabetes-Associated Pathologies, Current Molecular Medicine 2011; 11 (5) . https://dx.doi.org/10.2174/156652411795976565
DOI https://dx.doi.org/10.2174/156652411795976565 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets
Current Drug Targets The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Hypertension in Hemodialysis Patients
Current Hypertension Reviews Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes
Current Drug Targets CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Increased Risk of Falls, Fall-related Injuries and Fractures in People with Type 1 and Type 2 Diabetes - A Nationwide Cohort Study
Current Drug Safety Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued) Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Novel Sample Preparation for Mass Spectral Analysis of Complex Biological Samples
Current Proteomics Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Traditional and Novel Risk Factors of Diabetic Retinopathy and Research Challenges
Current Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Retinopathy in Pregnancy
Current Diabetes Reviews